{"organizations": [], "uuid": "89993cb0958ff0078116b9049d0db8859011734d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sorrento-therapeutics-audit-commit/brief-sorrento-therapeutics-audit-committee-concluded-cos-financial-statements-for-3-9-months-ended-sept-30-2017-should-not-be-relied-upon-idUSFWN1QH0Q8", "country": "US", "domain_rank": 408, "title": "BRIEF-Sorrento Therapeutics- Audit Committee Concluded Co's Financial Statements For 3 & 9 Months Ended Sept 30, 2017 Should Not Be Relied Upon​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T13:26:00.000+02:00", "replies_count": 0, "uuid": "89993cb0958ff0078116b9049d0db8859011734d"}, "author": "", "url": "https://www.reuters.com/article/brief-sorrento-therapeutics-audit-commit/brief-sorrento-therapeutics-audit-committee-concluded-cos-financial-statements-for-3-9-months-ended-sept-30-2017-should-not-be-relied-upon-idUSFWN1QH0Q8", "ord_in_thread": 0, "title": "BRIEF-Sorrento Therapeutics- Audit Committee Concluded Co's Financial Statements For 3 & 9 Months Ended Sept 30, 2017 Should Not Be Relied Upon​", "locations": [], "entities": {"persons": [{"name": "nantibody", "sentiment": "none"}, {"name": "sorrento", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-sorrento therapeutics- audit committee concluded co's financial statements for", "sentiment": "neutral"}, {"name": "sec", "sentiment": "none"}, {"name": "relied upon​ reuters staff", "sentiment": "none"}, {"name": "concluded co's financial statements for", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "sorrento therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News February 27, 2018 / 11:29 AM / in 11 minutes BRIEF-Sorrento Therapeutics- Audit Committee Concluded Co's Financial Statements For 3 & 9 Months Ended Sept 30, 2017 Should Not Be Relied Upon​ Reuters Staff 2 Min Read Feb 27 (Reuters) - Sorrento Therapeutics Inc: * SORRENTO THERAPEUTICS - ‍ON FEB 26, AUDIT COMMITTEE CONCLUDED CO‘S FINANCIAL STATEMENTS FOR 3 & 9 MONTHS ENDED SEPT 30, 2017 SHOULD NOT BE RELIED UPON​ * SORRENTO- ‍AN OTHER-THAN-TEMPORARY IMPAIRMENT IN VALUE OCCURRED IN EQUITY METHOD INVESTMENT IN IMMUNOTHERAPY NANTIBODY FOR 3 & 9 MONTHS ENDED SEPT 30 * SORRENTO THERAPEUTICS -NANTIBODY NOTIFIED CO THAT IN JULY IT ACQUIRED ASSETS FROM PARTY RELATED TO ITS 60% OWNER, FOR ABOUT $90 MILLION CASH -SEC FILING​ * SORRENTO THERAPEUTICS - ‍REASSESSED RECOVERABILITY OF CO‘S EQUITY METHOD INVESTMENT IN NANTIBODY AFTER NANTIBODY NOTIFIED CO OF JULY ACQUISITION​ * SORRENTO THERAPEUTICS INC - ‍IMPACT ON CO‘S 40% EQUITY INTEREST IN NANTIBODY IS A $36 MILLION IMPAIRMENT ON EQUITY METHOD INVESTMENT IN STATEMENT OF OPERATIONS * SORRENTO THERAPEUTICS INC - ‍ IMPAIRMENT EXPENSE RELATED TO NANTIBODY WILL NOT RESULT IN CASH EXPENDITURES IN PAST OR FUTURE PERIODS​ Source text: [ bit.ly/2GMrJy2 ] Further company coverage:", "external_links": [], "published": "2018-02-27T13:26:00.000+02:00", "crawled": "2018-02-27T13:48:24.012+02:00", "highlightTitle": ""}